1	The Effect of Diabetes Mellitus on the Pharmacokinetics of Tuberculosis Drugs
2	
3	
4	<b>Authors:</b> Muge Cevik <sup>1*</sup> , Ann Sturdy <sup>2</sup> , Bart G.J. Dekkers <sup>3</sup> , Onno W. Akkerman <sup>4,5</sup> , Stephen H.
5	Gillespie <sup>1</sup> , Jan 🛛 Willem C. Alffenaar <sup>6,7,8</sup>
6	
7	
8	Affiliations:
9	1. Division of Infection and Global Health Research, School of Medicine, University of St Andrews,
10	UK
11	2. Department of Infectious Disease, Faculty of Medicine, Imperial College London, UK
12	3. University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy
13	and Pharmacology, Groningen, the Netherlands
14	4. University of Groningen, University Medical Center Groningen, Department of Pulmonary
15	Diseases and Tuberculosis, Groningen, the Netherlands
16	5. University of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord,
17	Haren, the Netherlands
18	6. The University of Sydney Institute for Infectious Diseases, Sydney, NSW, Australia.
19	7. School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW,
20	Australia.
21	8. Westmead Hospital, Westmead, NSW, Australia
22	
23	*Corresponding author:
24	Dr Muge Cevik
25	Division of Infection and Global Health Research,
26	School of Medicine, University of St Andrews, Fife, KY16 9TF
27	Telephone number: +447732800814
28	Email address: mc349@st-andrews.ac.uk
29	
30	This is the first systematic review to comprehensively examine the impact of DM on the
31	pharmakokinetics of TB drugs. While some studies showed lower plasma concentrations, we
32	observed significant heterogeneity; therefore, no recommendations can be made.
33	

## 34 Abstract

35

36 While pharmacokinetics (PK) of many drugs is known to be altered in individuals with diabetes 37 mellitus (DM), the effects of DM on the PK of anti-tuberculosis (TB) drugs remains poorly 38 understood.

39

40 We performed a systematic review through searches of major databases from 1946 to 6 July 2023.

41 The literature search identified 4173 potentially relevant articles. After reviewing the eligibility

42 criteria, 21 articles were included that assessed the PK of anti-TB drugs among patients with DM.

43

44 Most articles focused on first line TB drugs; we identified 16 studies assessing rifampicin PK, 9 45 studies on isoniazid, 8 on pyrazinamide and 3 assessing ethambutol. Only 2 studies reported on 46 second line anti-TB treatment. While some studies showed lower plasma concentrations of TB 47 medications among DM patients, this finding was not consistent. In addition, we observed high 48 variability in findings and significant heterogeneity among studies in terms of study design and 49 differences in demographics.

50

51 This review provides detailed overview of the limited evidence available regarding the PK of anti-52 TB medications in patients with DM. However, due to significant heterogeneity between studies, 53 no conclusions could be made. Adequately designed PK studies using standardise methodologies 54 are urgently needed to make recommendations regarding drug dosing in patients affected both by 55 TB and DM.

56

57

58

59

60

### 62 Introduction

63

The global tuberculosis (TB) burden remains substantial, with more than 10 million people newly diagnosed per year [1]. TB patients often have other co-morbidities that influence the disease course and outcome. For instance, diabetes mellitus (DM) has been shown to increase the risk of acquiring TB [2, 3] and progression to active disease [3, 4]. The coexistence of TB and DM (TB-DM) has been associated with a 4-fold increased risk of treatment failure and 2-fold increased risk of death [5-7]. In addition, TB-DM patients have been shown to have a higher bacterial burden, delayed sputum culture conversion and a greater risk of developing drug resistance [6, 8].

71

Over the next 10 years, the prevalence of DM is estimated to double globally, affecting over 600 million individuals with a considerable increase in the African continent [9-11]. While DM has long been acknowledged as an important risk factor for TB, the threat posed by the burden of these two epidemics has recently been recognised [12, 13]. It is now considered a major global public health concern by the World Health Organization (WHO) and a critical public health challenge in low- and middle-income countries, with the WHO subsequently adopting a collaborative framework for care and control of TB and DM [14].

79

80 While the burden of TB and DM co-disease is increasing rapidly, there is limited practical evidence 81 to underpin guidelines for TB-DM patient management, such as length of treatment, drug dosing 82 and use of therapeutic drug monitoring (TDM). Pharmacokinetics (PK) of anti-TB agents show 83 inter- and intra-patient variability and co-morbidities may further influence plasma 84 concentrations, as the PK of many other drugs are known to be altered in diabetic individuals [15]. 85 DM may affect kidney function, gastric emptying and drug metabolism pathways [15, 16]. This 86 highlights the importance of understanding drug concentrations in TB-DM population as sub-87 therapeutic concentrations may contribute to the treatment failure and acquired drug resistance 88 [17].

89

In this systematic review, we evaluated the available evidence on the PK of antituberculosis drugs
in diabetic individuals to provide in-depth analysis to guide patient management and identify
priorities for research.

93

94 Methods

95

## 96 Search Strategy

97 We retrieved all original studies evaluating the effect of DM on the PK of all TB drugs 98 recommended by the WHO for the treatment of drug-sensitive (DS) and drug-resistant TB 99 including rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA) and/or ethambutol (EMB). We 100 systematically searched major databases; Medline, EMBASE, Web of Science and Scopus including conference abstracts from 1946 to 6<sup>th</sup> of July 2023 using Medical Subject Headings (MeSH) terms 101 (Supplementary Material). We also manually screened the references of included original studies 102 103 to obtain additional studies. To identify unpublished studies, http://clinicaltrials.gov was searched. 104 This systematic review was conducted in accordance with the Preferred Reporting Items for 105 Systematic Reviews and Meta-Analyses (PRISMA) statement. The protocol was registered at 106 PROSPERO (CRD42022323566).

107

## 108 Study Selection

109 Studies that reported PK of anti-TB medications among DM and non-DM participants were 110 included. No restrictions on language and publication date were applied. Studies in adult and 111 paediatric populations were included. General PK studies reporting a subgroup of DM participants 112 were not eligible unless they included detailed PK parameters for DM and non-DM participants. 113 Review articles, letters, case reports and case series with less than five participants and 114 correspondence were excluded, as were studies without PK data, drug interaction studies, and 115 non-human studies.

116

#### 117 Data Extraction

Two authors screened and retrieved articles according to the eligibility criteria and performed full text review and final article selection. From each study, the following variables were extracted: demographics of comparator group(s) and the DM group including age, weight, and sex, study design, DM diagnosis, and DM medications. Dose, dosing interval, sampling points, AUC, peak drug concentration (C<sub>max</sub>), half-life (t½), time to reach C<sub>max</sub> (T<sub>max</sub>), volume of distribution (Vd) and clearance (CL) were extracted from the included articles if available and were stratified by group. If these data were not reported, we also contacted the authors to request the data.

125

## 126 **Risk of bias in included studies**

127 In the absence of available tools to assess risk of bias in PK studies, we assessed study quality and 128 risk of bias using the ROBINS-I tool for non-randomised studies of interventions, which wasused to 129 assess PK studies in a recent publication [18, 19]. Any disagreements regarding grading of quality 130 were resolved through discussion with a third author.

131

## 132 Analysis

133 Narrative synthesis of the findings was conducted and reported according to the Synthesis 134 Without Meta-analysis (SWiM) guidelines [20]. Descriptive statistics was used to describe key 135 outcome measures. The data were found to be too heterogenous to permit further quantitative 136 synthesis.

137

#### 138 Results

139 The systematic search identified 4173 potentially relevant articles. After removing duplicates, 140 3464 articles were retrieved for initial screening of which a total of 49 studies were included for 141 full text review. After reviewing the eligibility criteria, 21 articles were included that assessed the 142 PK of anti-TB medications among TB-DM patients [21-41]. Five included papers presented the 143 same data: in conference abstract [42-46] and then in published form [23, 29, 33, 36, 43]; we 144 included data from the published report. One study was only published as a conference abstract 145 and the authors were not able to share more data at the time of this review [47]. No relevant 146 unpublished studies were found on the ClinicalTrials.gov. The study selection process is recorded 147 in a PRISMA flow diagram (Figure 1).

148

#### 149 **Rifampicin (Table 1)**

Of the 21 studies, 16 measured RIF plasma concentrations [21-23, 25, 27, 28, 30-36, 38-40], majority of which were prospective PK studies except one retrospective study reporting results based on routinely collected data [28]. RIF doses used were highly heterogeneous and are presented in Table 1.

154

Out of 16 studies, 7 reported AUC values; three studies with intensive sampling (> 6 samples) [31, 32, 38] reported AUC<sub>0-24</sub> mg.h/L, three studies reported AUC<sub>0-6</sub> mg.h/L [21, 33, 36], and one reported AUC<sub>0-8</sub> mg.h/L [27]. In one study, AUC<sub>0-6</sub> mg.h/L to RIF was significantly lower in patients with TB-DM compared to those without DM) [33], another study found a lower trend AUC<sub>0-24</sub> mg.h/L in the DM group, but this was not statistically significant [32] and five studies found no

difference [21, 27, 31, 34, 38]. Of the three studies carrying out intensive sampling [31, 32, 38], no
significant difference was shown.

162

Out of 16 studies, 15 measured RIF peak concentrations ( $C_{max}$ ); five demonstrated significantly lower RIF peak concentrations among diabetic patients compared to non-diabetics [22, 28, 33, 39, 40] and ten studies showed no significant difference between diabetic and non-diabetic patients [21, 25, 27, 30-32, 34-36, 38]. Mean absolute RIF  $C_{max}$  was below the recommended range (above 8 mg/L [48]) in diabetic and non-diabetic groups in the majority of studies, and within the recommended range only in the 3 studies with intensive sampling [31, 32, 38].

169

170 Eight studies measured the time to reach Cmax (T<sub>max</sub>), which was longer in TB-DM participants in 171 three studies [31-33] (although without reaching statistical significance in one study [33]) and 3 172 studies found no significant difference [34, 36, 38]. In a study using population PK modelling, 173 absorption rate constant (ka) was significantly increased and the volume of distribution (Vd) was 174 significantly increased in the DM [23], the authors inferring that the plasma concentrations would 175 therefore be lower in the DM group. Another study found no difference in ka or Vd between the 176 TB and TB-DM groups in a 1 compartment model, but reduced clearance was observed and Vd was 177 significantly higher in the TB-DM group when Vd was normalized to total body weight [31].

178

Raised blood glucose was inversely correlated with the rifampicin AUC/C<sub>max</sub> in four studies [31, 33, 39, 40], whereas three other studies found no association between HbA1c or fasting blood glucose (FBG) and plasma concentrations [25, 32, 38]. Two studies found that body weight and plasma concentrations were inversely correlated [22, 33].

183

## 184 Isoniazid (Table 2)

Nine studies assessed isoniazid (INH) PK [21, 22, 26-28, 30, 32, 35, 37]. Of these, one was based on
routinely collected retrospective data [28], four studies used 600 mg dosing 3 times per week [21,
27, 30, 35] and only 1 study sampled intensively [32]. Four studies assessed for NAT2 status using
different methods [26, 27, 32, 37]. We identified no studies with PK modelling.

189

Out of nine studies, four assessed the mean exposure; one  $AUC_{0.24}$  mg.h/L [32], two  $AUC_{0.6}$  mg.h/L [21, 37] and one  $AUC_{0.8}$  mg.h/L [27]. Of these, two studies demonstrated significantly lower mean exposure to INH [21, 32], although after adjustment for age, sex, and weight this difference

disappeared in one [21]. Two studies found no significant difference between the DM and non-DM groups [27, 37]. Four studies found INH  $C_{max}$  to be significantly lower in the DM group [21, 22, 30, 32], though one reported no significant difference after adjustments for age, sex, and weight [21] and the remaining 4 studies found no significant difference [26-28, 37]. One study with intensive sampling found no significant difference [32]. Out of three studies assessing  $T_{max}$ , one found no significant difference in INH  $T_{max}$  between the DM and non-DM group , and two studies did not report comparative analysis [27, 37].

200

201 While one study reported concentrations to be negatively correlated with blood glucose [30], in 202 two studies INH  $C_{max}$ /AUC was not correlated with FBG or HbA1c [26, 32]. In one study INH 203 concentrations were inversely correlated with weight [22].

204

## 205 Pyrazinamide (Table 3)

206 Pyrazinamide PK was reviewed in eight studies [21, 22, 27, 29, 30, 32, 35, 38], all of which were 207 prospective PK studies. Patients in all studies except two were on 1500 mg PZA dosing, whilst one 208 study used 1600 mg for patients >50 kg and 1200 mg for patients <50 kg [32] and other used 20-30 209 mg/kg [29]. Out of eight, four papers reported mean exposure to PZA; two reporting  $AUC_{0.24}$ 210 mg.h/L [32, 38], one AUC<sub>0-8</sub> mg.h/L [27] and one AUC<sub>0-6</sub> mg.h/L [21]. Mean exposure to PZA was 211 significantly lower among DM participants in two studies [21, 27] and two studies with intensive 212 sampling reported no significant difference in AUC<sub>0-24</sub> mg.h/L [32, 38]. Out of six studies reporting 213  $C_{max}$  three reported significantly lower  $C_{max}$  among DM compared to non-DM participants [21, 27, 214 30], which remained significant after adjustments for age, sex, and weight [21] and three studies 215 reported no significant difference [22, 32, 38]. Three studies measured T<sub>max</sub> and none reported a 216 statistically significant difference in T<sub>max</sub> between the DM and non-DM TB groups.

217

No correlation between FBG and AUC/C<sub>max</sub> was observed in two studies [32, 38] whereas one study showed a negative correlation between plasma PZA concentrations and blood glucose [30]. In a population PK modelling study [29], increased apparent clearance was observed in TB-DM patients, most significantly in the group with patients >70 years and AUC<sub>0-24</sub> mg.h/L was decreased in the DM group >70 years.

223

## 224 Ethambutol (Table 4)

Three included studies assessed the effect of DM on EMB PK [22, 32, 38]. Two reported  $AUC_{0-24}$ mg.h/L and  $T_{max}$  [32, 38], all reported  $C_{max}$ . None of the studies reported statistically significant difference in AUC,  $C_{max}$ , and  $T_{max}$  between the DM and non-DM groups. No correlation was seen between FBG and  $AUC/C_{max}$  in two studies [32, 38]. We identified no studies with PK modelling.

229

## 230 Other agents (Table 5)

231 Two studies assessed the effect of DM on other agents; cycloserine [41], linezolid [41] and 232 moxifloxacin [24]. A retrospective cross-sectional study reviewing the cycloserine and linezolid 233 drug levels at 2 h post-dose in routine practice found that 55% of the samples had below the lower 234 limit of recommended cycloserine plasma concentrations and 17% had low linezolid 235 concentrations [41]. DM patients had a lower cycloserine exposure, although this was not 236 statistically significant, and there was no association between linezolid exposure and DM. In a 237 recent retrospective study evaluating moxifloxacin PK,  $AUC_{0-24h}$  was shown to be significantly 238 lower in patients with DM compared to age, sex and RIF matched TB patients without DM [24]. In 239 line, peak and trough concentrations were also reduced in DM patients. Although the drug 240 absorption, volume of distribution and  $T_{max}$  were comparable between TB-DM and TB patients, 241 moxifloxacin clearance was increased in TB-DM patients. Comparison of area under the unbound 242 drug concentration-time curve/minimal inhibitory concentration (MIC) ratio indicate that 243 exposure was already low in the majority of control patients, but none of the DM patients had 244 adequate exposure to moxifloxacin.

245

## 246 **Risk of bias assessment**

247 The risk of bias for each domain across all included studies is given in Supplementary material. 248 Prospective studies were the most common study design contributing to the review question, 249 except three studies where routinely collected TDM was used. While all studies have made a 250 comparative analysis between DM and non-DM population, all studies had moderate to serious 251 risk of bias in at least one domain. There was a high risk of bias for baseline confounders that may 252 have influenced the outcome result. For example, 11 out of 21 studies did not match DM and non-253 DM groups according to age or sex. Non-adjustment of host factors may influence the plasma 254 concentrations, making it challenging to relate outcomes of the results to the effect of DM alone. 255 In addition, while most of the patients were on anti-diabetic medications, the degree of diabetic 256 control was not provided in the majority of studies. This highlights the challenges in studying the 257 PK of anti-TB medications in a patient population with complex background. Importantly, there

was also high risk of measurement bias in all prospective studies except three where intensive sampling was conducted. As a result, evidence quality is influenced due to confounding and imprecision, limiting our practice recommendations. Overall, the existing body of literature examining PK of anti-TB medications among DM population is of medium quality.

262

### 263 **Discussion**

264

This systematic review provides a comprehensive account of the impact of DM on the PK of anti-TB medications. Our findings suggest that the limited available evidence to date is highly variable. While some studies showed lower plasma concentrations of TB medications among DM patients, we observed high variability in findings and significant heterogeneity among studies including study design and differences in demographics. Therefore, no recommendation can be made.

270

271 There may be several reasons to explain this heterogeneity. Firstly, there were significant 272 demographic differences including weight, age and DM definitions. Increased body surface area 273 distribution and delayed drug absorption due to DM related gastroparesis and changes in 274 expression of enzymes involved in metabolism [49, 50] are major factors that may contribute to 275 altered PK [15, 16]. DM patients had higher weight and/or BMI compared to nondiabetic patients 276 and some studies demonstrated a negative association between weight and plasma 277 concentrations. The only study that matched based on weight (within 5 kg) [38] found no 278 significant difference of RIF plasma concentrations between groups. However, matching weight is 279 unlikely to eliminate potential biases as DM participants continued to receive capped dosing 280 despite weight differences and were also generally older than non-DM controls.

281

282 Unclear DM definitions may also explain the variability. In many studies DM diagnosis was based 283 on self-report. This is specifically important as self-reporting may not be accurate and secondly, TB 284 could lead to stress-induced hyperglycaemia, which resolves after TB treatment [51]. Screenning 285 DM at the time of TB diagnosis may result in some with transient hyperglycaemia being identified 286 as DM. Therefore, a standard measure of DM consistently defined and reported in PK studies in 287 line with the UNION criteria [52] would facilitate a better assessment of the plasma 288 concentrations [53]. Nevertheless, patients with transient hyperglycaemia may also be at risk of 289 lower plasma concentrations. For instance, in a study from Uganda, FPG was inversely correlated

with RIF AUC<sub>0-24h</sub> [54]. In addition, quality of diabetes control or treatment was poorly reported in
 most studies, which may have influenced the results.

292

PK sampling methodology and analysis varied widely. Studies with a single 2 hr sampling point assume  $T_{max}$  to occur at 2 hrs ( $C_{max}$ ). As  $T_{max}$  was longer for rifampicin in some studies, studies without intensive sampling may not accurately capture the  $C_{max}$ . Notably, 3 studies with intensive sampling [31, 32, 38] showed no differences in rifampicin or pyrazinamide  $C_{max}$ , but a significant difference in isoniazid  $C_{max}$  (27). However, it is important to note  $T_{max}$  is highly variable for RIF in general [55]

299

Particularly affecting the isoniazid studies, dosing differed markedly, with 4 out of 9 papers using 600 mg 3 times/week, which is no longer a recommended dosing, making the comparison between the studies and the generalisation of the results more difficult. Only four out of 9 studies made any assessment of NAT2 acetylator status. As this is recognised as a key variable in isoniazid PK, this is likely to confound any other comparison of variables [56].

305

Plasma concentrations of TB medications may affect the clinical outcome. Zheng et al [57] showed an association between plasma concentrations of first line anti-TB drugs and culture conversion and clinical outcomes and Alfarisi et al. [21] demonstrated a positive association between time to culture conversion and INH and RIF concentrations and negatively association with PZA levels in DM patients. In another retrospective study, where all DM patients underwent TDM and dose adjustment accordingly, time to culture conversion improved significantly greater among DM patients with the post-intervention group that converted on average 19 days earlier [58].

313

We identified another systematic review assessing the impact of DM on the PK of rifampicin among TB patients [59]. The review included studies published up until September 2020 and identified seven studies from which pooled estimates were calculated. The same authors updated their systematic review including studies with C<sub>max</sub> at 2hr [60], and identified 17 studies reporting RIF plasma concentrations. Our review considers studies published up to July 2023 with a comprehensive systematic search; therefore, we were able to identify 16 papers assessing the PK of RIF.

To our knowledge, this is the first review to comprehensively examine the impact of DM on the PK of TB drugs. Our study has limitations. Firstly, we identified a limited number of PK studies among DM patients despite a comprehensive literature search. Secondly, due to the substantial study heterogeneity we were unable to pool data. Finally, we did not include general PK studies reporting on TB-DM patients as a subgroup as detailed and comparative PK parameters for DM vs non-DM patient populations weren't available.

328

329 This review provides detailed understanding about the evidence available so far on PK of anti-TB 330 drugs in patients with DM. There is some evidence that PK, especially among DM patients, may 331 have clinical relevance in terms of MIC and culture conversion. However, significant heterogeneity 332 observed in studies and the scarcity of data on clinical outcomes, it is challenging to make 333 recommendations about dosing in the TB-DM population. Given the relationship of delayed 334 culture conversion and relapse, clinical outcomes should be explored in future PK studies. In order 335 to achieve definitive answers for PK in DM population, we recommend important considerations 336 as in **Table 6**. Until we have further information to guide the management of TB-DM patients, 337 TDM and dose adjustment may be beneficial in patients with DM.

338

## 339 Acknowledgements

This work was supported by the Chief Scientist Office (CAF/20/03) and British Infection Association
 (Grant/2022/SPG/MC) received by MC.

342

## 343 Author contributions

MC and SHG conceptualized the scope of the review. MC and AS pulled the data from selected papers. All authors contributed to the final version of the manuscript and approved it for publication.

347

#### 348 **Declaration of Interests**

349 No conflict of interests reported.

## 351 **References:**

353	1.	WHO. World Health Organization, Global tuberculosis report 2022
354	. Avail	able at: https://www.who.int/publications/i/item/9789240061729.
355	2.	Koesoemadinata RC, McAllister SM, Soetedjo NNM, et al. Latent TB infection and
356		pulmonary TB disease among patients with diabetes mellitus in Bandung, Indonesia. Trans
357		R Soc Trop Med Hyg <b>2017</b> ; 111(2): 81-9.
358	3.	Foe-Essomba JR, Kenmoe S, Tchatchouang S, et al. Diabetes mellitus and tuberculosis, a
359	-	systematic review and meta-analysis with sensitivity analysis for studies comparable for
360		confounders PLoS One <b>2021</b> : 16(12): e0261246
361	4	Al-Rifai RH Pearson F Critchley IA Abu-Raddad LI Association between diabetes
362		mellitus and active tuberculosis: A systematic review and meta-analysis PL oS One 2017:
363		12(11): $a0187967$
364	5	Baker MA Harries AD Jeon CV et al. The impact of diabetes on tuberculosis treatment
265	5.	outcomes: a systematic raviow <b>PMC</b> Med <b>2011</b> : 0: 81
266	6	Solindri AD Vinioni M Kompker DD et al Dishetes Deduces the Dete of Sputum Culture
200	0.	Sannori AD, Kipiani M, Kempker KK, et al. Diabetes Reduces the Rate of Sputum Culture
30/		Conversion in Patients with Newly Diagnosed Multidrug-Resistant Tuberculosis. Open
368	-	Forum Infect Dis 2016; $3(3)$ : OFW126.
369	1.	Huangtu P, Ugarte-Gil C, Golub J, Pearson F, Critchley J. The effects of diabetes on
370		tuberculosis treatment outcomes: an updated systematic review and meta-analysis. Int J
371		Tuberc Lung Dis 2019; 23(7): 783-96.
372	8.	Dong Z, Shi J, Dorhoi A, et al. Hemostasis and Lipoprotein Indices Signify Exacerbated
373		Lung Injury in TB With Diabetes Comorbidity. Chest <b>2018</b> ; 153(5): 1187-200.
374	9.	Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes
375		prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract <b>2018</b> ; 138: 271-81.
376	10.	Collaboration NCDRF. Worldwide trends in diabetes since 1980: a pooled analysis of 751
377		population-based studies with 4.4 million participants. Lancet <b>2016</b> ; 387(10027): 1513-30.
378	11.	Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active
379		tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with
380		tuberculosis. Lancet Glob Health 2019; 7(4): e448-e60.
381	12.	Pan SC, Ku CC, Kao D, Ezzati M, Fang CT, Lin HH. Effect of diabetes on tuberculosis
382		control in 13 countries with high tuberculosis: a modelling study. Lancet Diabetes
383		Endocrinol <b>2015</b> ; 3(5): 323-30.
384	13.	Harries AD, Kumar AM, Satyanarayana S, et al. Addressing diabetes mellitus as part of the
385		strategy for ending TB. Trans R Soc Trop Med Hyg <b>2016</b> ; 110(3): 173-9.
386	14.	WHO. Integrated care for tuberculosis (TB) and diabetes mellitus (DM) comorbidity in
387		Asian countries: health system challenges and opportunities
388	. 2022.	
389	15.	Dostalek M. Akhlaghi F. Puzanovova M. Effect of diabetes mellitus on pharmacokinetic and
390		pharmacodynamic properties of drugs Clin Pharmacokinet <b>2012</b> : 51(8): 481-99
391	16	Gwilt PR Nahhas RR Tracewell WG The effects of diabetes mellitus on pharmacokinetics
392	10.	and pharmacodynamics in humans. Clin Pharmacokinet <b>1991</b> : 20(6): 477-90
303	17	Gillespie SH. Evolution of drug registance in Mycobacterium tuberculosis: clinical and
30/	17.	molecular perspective. Antimicrob Agents Chemother 2002: 46(2): 267.74
305	18	Storme IA Hormen MA Deeves BC at al DOBINS I: a tool for assessing rick of higs in
206	10.	non rendomised studies of interventions <b>DMI 2016</b> : 255: i4010
207	10	Cafer E. Wasmann DE. Malllaron HM, et al. Clabal actimates and determinents of
200	19.	ontituberoulogic drug phormosolcineties in children and adalassents: a systematic matter and
370 200		annuoterculosis drug pharmacokinetics in children and adolescents: a systematic review and individual national data mata analysis. Eur Despin L 2022, (1/2)
399	20	murviduai patient data meta-analysis. Eur Kespir J <b>2023</b> ; 01(3).
400	20.	Campbell WI, WICKENZIE JE, Sowden A, et al. Synthesis without meta-analysis (SW1M) in
401		systematic reviews: reporting guideline. BMJ 2020; 368: 16890.

402 403	21.	Alfarisi O, Mave V, Gaikwad S, et al. Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment. Antimicrob Agents Chemother <b>2018</b> ;
404		62(11): 11.
405	22.	Babalik A, Ulus IH, Bakirci N, et al. Plasma concentrations of isoniazid and rifampin are
406		decreased in adult pulmonary tuberculosis patients with diabetes mellitus. Antimicrob
407		Agents Chemother <b>2013</b> ; 57(11): 5740-2.
408	23.	Chang MJ, Chae JW, Yun HY, et al. Effects of type 2 diabetes mellitus on the population
409		pharmacokinetics of rifampin in tuberculosis patients. Tuberculosis (Edinb) 2015; 95(1): 54-
410		9.
411	24.	Dekkers BGJ, Bolhuis MS, Beek LT, et al. Reduced moxifloxacin exposure in patients with
412		tuberculosis and diabetes. European Respiratory Journal 2019; 54(3) (no pagination).
413	25.	Fonseca AAD, Pinto ACG, Paixao TPD, Alberio CAA, Vieira JLF. Can diabetes mellitus
414		modify the plasma concentrations of rifampicin in patients under treatment for tuberculosis?
415		Brazilian Journal of Infectious Diseases 2020; 24(4): 352-5.
416	26.	Galvao FES, Fonseca AAD, Pinto ACG, da Paixao TP, Alberio CAA, Vieira JLF. No
417		significant influence of diabetic mellitus on isoniazid plasma levels in patients under
418		treatment for tuberculosis. Infectious Diseases <b>2020</b> ; 52(8): 577-80.
419	27.	Hemanth Kumar AK, Kannan T, Chandrasekaran V, et al. Pharmacokinetics of thrice-
420		weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India. Int J
421		Tuberc Lung Dis <b>2016</b> : 20(9): 1236-41.
422	28.	Hevsell SK, Moore JL, Keller SJ, Houpt ER, Therapeutic drug monitoring for slow response
423		to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 2010:
424		16(10): 1546-53.
425	29.	Kim R. Javanti RP. Kim HK, et al. Development of a population pharmacokinetic model of
426	_,.	pyrazinamide to guide personalized therapy: impacts of geriatric and diabetes mellitus on
427		clearance. Front Pharmacol <b>2023</b> : 14 (no pagination): 1116226.
428	30.	Kumar AK. Chandrasekaran V. Kannan T. et al. Anti-tuberculosis drug concentrations in
429	200	tuberculosis patients with and without diabetes mellitus. Eur I Clin Pharmacol <b>2017</b> : 73(1):
430		65-70.
431	31.	Medellin-Garibay SE, Cortez-Espinosa N, Milan-Segovia RC, et al. Clinical
432	011	Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus:
433		Association with Biochemical and Immunological Parameters. Antimicrob Agents
434		Chemother <b>2015</b> : 59(12): 7707-14.
435	32.	Mtabho CM. Semvua HH, van den Boogaard L et al. Effect of diabetes mellitus on TB drug
436	021	concentrations in Tanzanian patients. J Antimicrob Chemother <b>2019</b> : 74(12): 3537-45.
437	33.	Nijland HM, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is strongly reduced in
438		nations with tuberculosis and type 2 diabetes Clin Infect Dis <b>2006</b> : 43(7): 848-54
439	34.	Perea-Jacobo R. Muniz-Salazar R. Laniado-Laborin R. Cabello-Pasini A. Zenteno-Cuevas
440	511	R Ochoa-Teran A Rifampin pharmacokinetics in tuberculosis-diabetes mellitus patients: a
441		nilot study from Baja California Mexico. Int I Tuberc Lung Dis <b>2019</b> : 23(9): 1012-6
442	35	Ramachandran G. Chandrasekaran P. Gaikwad S. et al. Subtherapeutic rifampicin
443	55.	concentration is associated with unfavorable tuberculosis treatment outcomes. Clin Infect
444		Dis $2020$ , $70(7)$ , $1463-70$
445	36	Requenta-Mendez A Davies G Ardrey A et al Pharmacokinetics of rifampin in Peruvian
446	50.	tuberculosis patients with and without comorbid diabetes or HIV Antimicrob Agents
447		Chemother <b>2012</b> : 56(5): 2357-63
448	37	Requenz-Mendez A Davies G Waterhouse D et al Effects of dosage comorbidities and
440 449	57.	food on isoniazid pharmacokinetics in Peruvian tuberculosis patients. Antimicrob Agents
450		Chemother <b>2014</b> : 58(12): 7164-70
451	38	Ruslami R Niiland HM Adhiarta IG et al Pharmacokinetics of antituberculosis drugs in
452	50.	nulmonary tuberculosis natients with type 2 diabetes Antimicroh Agents Chemother <b>2010</b> .
453		54(3)· 1068-74
155		

454	20	
454	39.	Samuel Gideon George P, Saranya P. Effect of patient-specific variables on ritampicin peak
455	10	serum concentration. Drug Invention Today <b>2018</b> ; 10(3): 290-6.
456	40.	Saranya P, Parthasarathy V, Hariprasad B, Shobha Rani H. Effect of diabetes mellitus on
457		rifampicin peak serum concentration. International Journal of Pharmacy and Pharmaceutical
458		Sciences <b>2016</b> ; 8(10): 149-52.
459	41.	Zhu H, Guo SC, Liu ZQ, et al. Therapeutic drug monitoring of cycloserine and linezolid
460		during anti-tuberculosis treatment in Beijing, China. Int J Tuberc Lung Dis <b>2018</b> ; 22(8):
461		931-6.
462	42.	Chang MJ, Shin W, Song J, et al. The pharmacokinetics of four standard anti-tuberculosis
463		drugs in tuberculosis patients with diabetes mellitus. Respirology <b>2009</b> ; 3): A231.
464	43.	Mtabho C, Semvua H, Kibiki G, Tostmann A, Aarnoutse R. The effect of diabetes mellitus
465		on the pharmacokinetics of tuberculosis drugs in Tanzanian patients. Tropical Medicine and
466		International Health <b>2015</b> ; 1): 23.
467	44.	Nijland H, Ruslami R, Stalenhoef J, et al. Exposure to rifampicin is reduced by 53% in
468		tuberculosis patients with Diabetes Mellitus. Br J Clin Pharmacol 2006; 62(6): 730
469	45.	Mendez AR, Moore DAJ, Davies G. Improving management of TB in the tropics
470		Rifampicin pharmacokinetics in peruvian tuberculosis patients with and without co-morbid
471		diabetes or HIV. Tropical Medicine and International Health <b>2011</b> ; 1): 62.
472	46.	Kim R, Jayanti R, Jang T, et al. Development of Population Pharm Aco Kin Etics Model of
473		Pyrazinamide and Optimal Dose Recommendation for Elderly with Diabetes Mellitus in
474		Korean Tuberculosis Patients. Clinical Pharmacology and Therapeutics 2023;
475		113(Supplement 1)(S1): S94.
476	47.	Christopher DJ, Jedidiah D, Isaac B, Mathew B, Winston B. Anti-tubercular drug
477		concentrations in pulmonary tuberculosis patients-diabetic vs non-diabetic groups. European
478		Respiratory Journal Conference: 29th International Congress of the European Respiratory
479		Society, ERS Madrid Spain 2019; 54(Supplement 63).
480	48.	Peloquin CA, Velasquez GE, Lecca L, et al. Pharmacokinetic Evidence from the HIRIF
481		Trial To Support Increased Doses of Rifampin for Tuberculosis. Antimicrob Agents
482		Chemother <b>2017</b> ; 61(8).
483	49.	Kuppusamy UR, Indran M, Rokiah P. Glycaemic control in relation to xanthine oxidase and
484		antioxidant indices in Malaysian Type 2 diabetes patients. Diabet Med <b>2005</b> ; 22(10): 1343-
485		6.
486	50.	Dash RP, Ellendula B, Agarwal M, Nivsarkar M. Increased intestinal P-glycoprotein
487		expression and activity with progression of diabetes and its modulation by epigallocatechin-
488		3-gallate: Evidence from pharmacokinetic studies. Eur J Pharmacol <b>2015</b> ; 767: 67-76.
489	51.	Ugarte-Gil C, Alisiahbana B, Ronacher K, et al. Diabetes mellitus among pulmonary
490		tuberculosis patients from four TB-endemic countries: the TANDEM study. Clin Infect Dis
491		2019.
492	52.	Lin Yan ADH, Ajay M V Kumar, Julia A Critchley, Reinout van Crevel, Philip Owiti, Riitta
493		A Dlodlo, Anders Deigaard, MANAGEMENT OF DIABETES MELLITUS-
494		TUBERCULOSIS - A GUIDE TO THE ESSENTIAL PRACTICE
495	. 2019	
496	53.	LinY HAD, Kumar A MV, Critchley J A, van Crevel R, Owiti P, Dlodlo R A, Dejgaard A.
497		Management of diabetes mellitus-tuberculosis: a guide to the essential practice. International
498		Union Against Tuberculosis and Lung Disease 2019.
499	54.	Wyrsch F, von Braun A, Sekaggya-Wiltshire C, et al. Hyperglycaemia and
500	-	pharmacokinetics of rifampicin/isoniazid among TB-HIV co-infected patients in Kampala.
501		Uganda. Int J Tuberc Lung Dis <b>2020</b> ; 24(12): 1234-40.
502	55.	Sturkenboom MG, Mulder LW, de Jager A, et al. Pharmacokinetic Modeling and Optimal
503		Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with
504		Tuberculosis. Antimicrob Agents Chemother <b>2015</b> : 59(8): 4907-13.

505 506 507	56.	Hong BL, D'Cunha R, Li P, et al. A Systematic Review and Meta-analysis of Isoniazid Pharmacokinetics in Healthy Volunteers and Patients with Tuberculosis. Clin Ther <b>2020</b> ; 42(11): e220-e41.
508	57.	Zheng X, Bao Z, Forsman LD, et al. Drug Exposure and Minimum Inhibitory Concentration
509		Predict Pulmonary Tuberculosis Treatment Response. Clin Infect Dis 2021; 73(9): e3520-
510		e8.
511	58.	Alkabab Y, Keller S, Dodge D, Houpt E, Staley D, Heysell S. Early interventions for
512		diabetes related tuberculosis associate with hastened sputum microbiological clearance in
513		Virginia, USA. BMC Infect Dis <b>2017</b> ; 17(1): 125.
514	59.	Metwally AS, El-Sheikh SMA, Galal AAA. The impact of diabetes mellitus on the
515		pharmacokinetics of rifampicin among tuberculosis patients: A systematic review and meta-
516		analysis study. Diabetes Metab Syndr 2022; 16(2): 102410.
517	60.	El-Sheikh SMA, Metwally AS, Galal AAA. Impact of diabetes mellitus on rifampicin's
518		plasma concentration and bioavailability in patients with tuberculosis: A systematic review
519		and meta-analysis study. Therapie 2023; 78(3): 313-24.
520		





From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.

													medRxiv (whic					
Study	Country	Study Design	Number (DM/Total)	Age	Sex	Weight	Sampling	TB Treatment Phase	Dose (mg)	Regimen	TB Diagnosis	DM Diagnosis	C <sub>max</sub> C <sub>max</sub> n	AUC	T <sub>max</sub> (Hrs)	DM Control	DM Treatment	Other PK
Nijland 2006	Indonesia	Prospective PK	17/34	Matched Median 50 (DM) v 48 (nonDM)	Matched (59% male)	Significantly higher in DM group (median kg 55.6 versus 46.2 p0.01)	2/4/6 hr	Continuation	450	Rifampicin 450mg Isoniazid 300mg 3x week	Pulmonary Microbiologically confirmed	Known Screening via FBGx2	mg/L Significantly Identify Mean 3.49 (2.8 6.3 95% CI) DM v 578 (5.6 – 10.1) nonDM p0.00	0-6h mg x h/L Significantly lower in DM group 12.3 (8.0-24.2) DM v 25.9 (21.4-40.2) nonDM p0.003	T <sub>max</sub> longer in DM group, but not significant Median 4 (2-6 range) DM v 2 (2-4) nonDM, p0.52	Median HbA1c 9.85% Median FBG 9.3mmol/L	71% on oral antidiabetic meds. No metformin or insulin	Body weight, raised FBG, DM inversely correlated with AUC/C <sub>max</sub> on MV analysis
R usl ami 2010	Indonesia	Prospective PK	17/34	Significantly higher DM group Mean 47 (DM) versus 35 (nonDM) p0 00	Matched (42% male)	Matched (within 5kg) (mean 47.3kg both groups)	Intensive	Intensive	450	Rifampicin 450mg Isoniazid 300mg Pyrazinamide 1500mg Ethambutol 750mg Daily	Pulmonary	Known (60%) Screening via WHO criteria (40%)	110.1101/2023.08   11:07/2023.08   12:395% C日時 2015   12:395% C日時 2015   12:395% C日時 2015   11:07/2023.08   11:07/2023.08	0-24 mg x h/L No difference Mean 49.0 (40.9- 58.7) DM v 50.6 (42.9-59.8) nonDM p0.81	No difference Median 2 (0.5-4 range) DM v 2.5 (1-4) nonDM p0.28	Mean HbA1c 11.1% Median FBG 16.6mmol/L	None	No correlation between FBG and AUC/C <sub>max</sub> 10 DM cases treated with insulin to achieve glycaemic control, with PK repeated 6 weeks later – non-significant change in AUC/other PK Has further detailed PK if needed
Heysell 2010	USA	Retrospective cohort using routinely collected data TDM carried out for patients defined as 'slow to respond'	17/42	36% 18-39, 36% 40-54, 28% >65 Total group – no break down for DM	67% male of total group (nil breakdown for DM)	Unknown	2 hr	Unknown	Unknown	Rifampicin Isoniazid Pyrazinamide Ethambutol Some daily, some 2x week R/H	Pulmonary or extrapulmonary Microbiologically confirmed	Unknown	C <sub>max</sub> defined above sample bio Normal range defined above year above provide the sample of the sample provide the sample of the sample of the sample provide the sample of the sample	NA	NA	Unknown	Unknown	No quantitive C <sub>max</sub> data available comparing DM and non-DM groups
Requen a- Mendez 2012	Peru	Prospective comparing DM group, HIV group and non- DM/HIV group	26/105 (29 HIV, 50 nonDM/ nonHIV)	Significantly higher in DM group (51.3 versus 31.1 nonDM/HIV)	65.4% male DM group, 48.0% nonDM/HIV)	BMI reported rather than weight. Significantly higher in DM group (27.5 versus 23.3 nonDM/nonHIV group)	2hr, 6hrs	1 time point for each case, 61/105 intensive, 44/105 continuous (50% each in DM group)	10mg/kg to maximum 600	Rest of regimen not stated x6/week dosing in intensive, x2/week in continuation	87% pulmonary, 77/105 microbiologically confirmed	Known	mg/L mg/L Cm ax taken highest of 2017 Ghr sample Modifferent Cmax mean at Cmax	NA	6hrs rather than 2hrs in 62.2% cases (no association with DM)	Median HbA1c 8.3%	Unknown	Majority of patients with concentrations lower than therapeutic range – no particular association with DM.
Babalik 2013	Turkey	Prospective	14/70	Significantly higher in DM group (56.5yrs versus 39.0, p0.001)	86% DM group male, versus 61% non-DM (p0.116	DM group significantly heavier (68.7kg versus 56.7kg, p0.001)	2hr4	Intensive at 14 and 30 days after starting treatment	600	600 Rifampicin 300 Isoniazid 1500 Pyrazinamide 1000 Ethambutol Daily	Pulmonary, 89% culture confirmed	Known	C2hr only Significantly low in DM group at 0 D14 and D30 (day 14 mean 5.1 µg/mL nonDM, 2.9 DM, p<0.05, day 30 mean 5.4 nonDM versus 3.2	NA	NA	Mean HbA1c 6.1% (only included if HbA1c <6.5%)	On treatment	Concentration inversely correlated with weight
Chang 2015	Korea	Prospective with analysis using population PK	21/54	Median 55 (20-92 range) for whole group, no breakdown of DM group	63% male whole group, no breakdown DM group	Mean 53.96kg whole group, no breakdown DM group	1,2,4,6hrs	Intensive	10 mg/kg (up to 450 mg or 600 mg)	Rifampicin 10 mg/kg (max 450 mg or 600 mg) Isoniazid 5 mg/kg (max 300 mg or 400 mg) Pyrazinamide 15-30 mg/kg (max 1500 mg) Ethambutol 15-20 mg/kg (max 800 mg, 1000 mg or 1200 mg) Daily	Combination dinical/radiologic al/microbiological	FBG >126 mg/dl or post-prandial glucose levels >200 mg/dl	DM, p<0.05)	NA	NA	Mean fasting blood glucose 154.8 mg/dL	Unknown	ka (absorption rate constant) significantly increased in DM group (2.81 hr-1, versus 1.33, p<0.05) Vd (volume of distribution) significantly increased in DM group (76.3L versus 46.1, p<0.05) Infer from increased Vd in DM group, that plasma concentration would be lower in DM group
Medelli n- Garibay 2015	Mexico	Prospective intensive PK with additional immunology study	24/48	DM group older Median 52.2 versus 37.3	Matched	Higher median BMI in DM group (23.3 versus 21.6)	Intensive	Intensive	450 if <50kg 600 if >50kg	Rifater 450/600 Rifampicin 225/300 Isoniazid 1200/1600 Pyrazinamide (Weight 50kg) per tablet	Microbiologically confirmed	Known or screened: fasting glucose >126 mg/dl or HbA1c >6.5%	Mg/L No significant difference Median Cmax DM group 12.10 ± 5.1 versus 11.41 ± 3.8, p0.44	AUC 0-24 (mg.hr.L) No significant difference Median DM group 97.52 ± 36.7 versus 82.60 ± 35.5, p0.17	Significantly increased in Dm group Median DM 2.98 ± 1.9 versus 2.32 ± 1.4	Median HbA1c 9.02%	63% on treatment	No difference in ka or VD between TB and TBDM group in 1 compartment model, but reduced clearance in Dm group Tlag significantly increased in Dm group Tlag positively correlated with increased HbA1c, Cmax negatively correlated with increased fasting glucose
Hemant h Kumar 2016	India	Prospective PK to assess x3 weekly regimen, with	23/101	Median age 34 (no breakdown of Dm group)	65.3% male (no breakdown of Dm group)	BMI significantly higher in Dm group (20.3 versus 18.4, p0.021)	2,4,6,8 hrs	Intensive	450 (600 if >60kg)	Rifampicin 450/600 Isoniazid 600 Pyrazinamide 1500 Ethambutol 1200	Pulmonary or EP	Known or random blood glucose >200 µg/mL	µg/mL No significant difference Median DM 5.7	AUC 0-8 μg/ml.hr No significant difference Median DM 27.6	2hrs for whole group – no analysis comparing DM	Unknown	Unknown	DM not significant as a factor on multivariate analysis (Cmax and AUC)

													me					
		DM as one covariate								+/- Streptomycin 750 3x weekly			(4.2 – 7.1) ver mox nonDM 4.9 (3 6.6), p0.24	(22.0-37.3) versus nonDM 27.9 (20.0- 32.7), p0.35	to nonDM			
Saranya 2016	India	Prospective PK	20/45	DM group older Mean 46.6 v 42.4	68.9% male (no breakdown of DM group)	Weight not significantly different between DM and nonDM (p=0.544), 89.9% total <50kg	2hr	Not specified	Not specified	Not specified	Pulmonary	Unknown	C2hr only or the control of the cont	NA	NA	Unknown	83% on insulin and metformin	Cmax negatively correlated with RBG
Kumar 2017	India	Prospective multicentre	452/1912	DM significantly older (median age DM 48yr versus 34, p<0.001)	Significantly more men in Dm group (73.5% versus 65.7, p0.002	BMI significantly higher in DM group (20.4 versus 18.2, p<0.001)	2hr	Intensive	450 (600 if >60kg)	Rifampicin 450/600 Isoniazid 600 Pyrazinamide 1500 Ethambutol 1200 +/- Streptomycin 750 3x weekly	Pulmonary or EP	Known or random blood glucose >200 µg/mL (16% new)	μg/mL C2hr only treview difference main and the second Median DM2 220 (0 7-4 9) 2000	NA	NA	Median random blood glucose 263.5 mg/dL	Majority of diabetes group on treatment	
Alfarisi 2018	India	Prospective cohort, both PK and PK-PD	101/243	DM significantly older (median age 48 versus 26, p<0.001)	Significantly more men in DM group (77% versus 61%, p<0.001)	Weight significantly increased in DM group (50.8kg versus 45kg, p<0.001)	0.5,2,6hrs	x1 intensive x1 continuation	450	Rifampicin 450 Isoniazid 600 Pyrazinamide 1500 Ethambutol 1200 3x weekly Rif/Iso alone in continuation (3x weekly)	Pulmonary	Known or HbA1c >6.5%, fasting blood glucose concentration >126 mg/dl, or random blood glucose >200 mg/dl	μg/mL and the authors of the authors difference of the authors intensive: new authors DM 3.63, new authors 4.32, p0.17 authors mean DM 3.84 ho b nonDM 2.980 b b p0.17	AUC0-6 µg.hr/ml No significant difference Intensive: mean DM 12.19, nonDM 15.34, p0.11 Continuation: mean DM 14.56, nonDM 11.13 p0.14	NA	Median HbA1c at baseline 8.9%	44.6% on metformin	
Samuel Gideon George 2018	India	Prospective PK	24/60	Mean 44.78yrs (no breakdown of DM group)	71.7% male (no breakdown of DM group)	Weight significantly increased in DM group (mean 50.87kg versus 42.36kg, p<0.001)	2hr	Intensive	450/600 (?weight cut off)	Rifampicin 450/600 Isoniazid Pyrazinamide Ethambutol 3x weekly Doses not specified	Pulmonary, smear and radiologically positve	Not stated	μg/mL Case of the side of the	NA	NA	Unknown	Unknown	Cmax negatively correlated with RBG
Mtabho 2019	Tanzania	Prospective PK	19/39	DM significantly older (median age 50yrs versus 38, p0.001)	No difference in groups (79% male in DM group versus 75%)	No difference in weight (58kg DM versus 55% non, p0.258)	Intensive	Intensive	600 (>50kg), 450 (<50kg)	Rifampicin 600/450 Isoniazid 300/225 Pyrazinamide 1600/1200 Ethambutol 1100/825 Weight cut off 50kg Daily	Clinical/radiologic al/microbiological	Known or fasting glucose >7mmol/L	mg/L icitized mg/L icitized No significant a icitized difference icitized Mean DM 70 12 12 20.7), nonDM 42 33 (5.9-14.8) p0 33	AUC0-24 mg.h/L Trend to lower in DM group but not significant Mean DM 29.9 (6.4- 69.7), nonDM 39.9 (27.4-68.3), p0.052	Significantly longer in DM Median DM 2.1hrs versus 1.1hrs, p0.02	Median HbA1c 111mmol/mol	84% on oral medications	Cmax/AUC not associated with fasting glucose or HbA1c results
Perea- Jacobo 2019	Mexico	Prospective PK	16/30	DM significantly older (mean age 46.6yrs versus 37.2, p0.018)	No difference between groups (75% male DM group versus 71%)	No difference in BMI (Mean DM 23.6 versus 22.3, p0.323)	2.5,6,24 hrs	Intensive	600	Rifampicin 600 Isoniazid 300 Pyrazinamide 1600 Ethambutol 1200 Daily	Pulmonary and extrapulm, micro confirmed	Fasting glucose >126 mg/dl or HbA1c >6.5%	µg/mL (Sp Co No significant av Co difference the co Mean DM 4.1@ 3.0, nonDM 5.00 pt 3.8, p0.37 € 2	AUCO-6 mg.h/l No significant difference Mean DM 14.3 ± 7.5, nonDM 21.6 ± 16.3, p0.13	No significant difference Mean DM 5.6± 7.3, nonDM 4.0 ± 6.1, p0.50	Unknown	88% on treatment	
Fonseca 2020	Brazil	Prospective PK	26/62	No difference (median 39yrs versus 44)	100%	Weight significantly higher in DM group (Median 64kg versus 54kg)	2hrs	Intensive/ Continuation (D61)	600	Rifampicin 600 Isoniazid 300 Pyrazinamide 1600 Ethambutol 1100 Daily R/H only in continuation	Pulmonary, clinical, radio, micro	Fasting glucose >126 mg/dl or HbA1c >6.5%	με/mL C2hr only No significant perfort difference Median DM 6.0 8.9 range), noffic 6.16 (3.0-14.2), pp. p0.37	NA	NA	Median HbA1c 9.6%	15% on treatment	No association between concentrations and HbA1c or FBG
R am ach andran 2020	India	Prospective PK, specifically looking at association between C <sub>2hr</sub> and outcomes.	113/404	Median age 40, no breakdown of DM group	64, no breakdown DM group	BMI Median 17.8, no breakdown DM group	2hrs	Intensive and Continuation	450/600 if >60kg	R 450/600 H 600 Z 1500 E 1200 3x weekly CP: R/H	Pulmonary	Known or HbA1c >6.5%, or RBG >200 mg/dl	μg/mL C <sub>2h</sub> No significant difference I: Median 3.64 (1.78- 6.58 IQR) v 3.47 (1.33- 6.40), p0.49 C: 5.91 (2.13-9.51) v 4.41 (1.65-7.46), p0.07	NA	NA	Unknown	Unknown	

Rifampicin

													(which was	medRxiv preprin	
	Country	Study Design	Number (DM/Total)	Age	Sex	Weight	Sampling	TB Treatment Phase	Dose (mg)	Regimen	TB Diagnosis	DM Diagnosis	C <sub>max</sub>	AUC	T <sub>max</sub> (Hrs)
ni	Indonesia	Prospective PK	18/36	Significantly higher DM group Mean 47 (DM) versus 35 (nonDM) p0.00	Matched (42% male)	Matched (mean 47.3kg both groups)	Intensive	Intensive	1500	Rifampicin 450mg Isoniazid 300mg Pyrazinamide 1500mg Ethambutol 750mg	Pulmonary	Known (60%) Screening via WHO criteria (40%)	mg/L No difference Mean 45.5 (41.6- 49.3 95% Cl) DM V 47.0 (44.1-50.1) nonDM p0.47	0-24 mg x h/L No difference Mean 409 (369- 455) DM v 468 (422-519) nonDM p0.07	No differ Median 1 range) DI (0.5-6) no p0.61
k	Turkey	Prospective	14/70	Significantly higher in DM group (56.5yrs versus 39.0, p0.001)	86% DM group male, versus 61% non-DM (p0.116	DM group significantly heavier (68.7kg versus 56.7kg, p0.001)	2hr	Intensive at 14 and 30 days after starting treatment	1500	600 Rifampicin 300 Isoniazid 1500 Pyrazinamide 1000 Ethambutol Daily	Pulmonary, 89% culture confirmed	Known	C2hr only No significant difference at Date and D30 (day 14 ) mean 23.4 µg/m p>0.05, day 30 Hogon 27.9 nonDM vector 23.4 DM, p>0.05	NA NA 10.1101/2023.08.29.2	NA
nth	India	Prospective PK to assess x3 weekly regimen, with DM as one covariate	23/101	Median age 34 (no breakdown of Dm group)	65.3% male (no breakdown of Dm group)	BMI significantly higher in Dm group (20.3 versus 18.4, p0.021)	2,4,6,8 hrs	Intensive	1500	Rifampicin 450/600 Isoniazid 600 Pyrazinamide 1500 Ethambutol 1200 +/- Streptomycin 750 3x weekly	Pulmonary or EP	Known of random blood glucose >200 μg/mL	μg/mL     Offur       Significantly lowered     DM       DM group     Off       Median DM 36.49     Off       (28.8 - 41.6) verge     Off       nonDM 40.5 (34.6)     Off       45.0), p0.007.     Off       DM non-significant     Off       analysis     Off	AUC 0-8 µg/ml.hr Significantly lower in DM group Median DM 192.6 (158.4-230.4) versus nonDM 232.3 (206.0- 256.1-61.1), p<0.001 DM non- significant on multivariate analysis	2hrs for v group – n analysis comparin nonDM
r	India	Prospective multicentre	452/1912	DM significantly older (median age DM 48yr versus 34, p<0.001)	Significantly more men in Dm group (73.5% versus 65.7, p0.002	BMI significantly higher in DM group (20.4 versus 18.2, p<0.001)	2hr	Intensive	1500	Rifampicin 450/600 Isoniazid 600 Pyrazinamide 1500 Ethambutol 1200 +/- Streptomycin 750 3x weekly	Pulmonary or EP	Known or random blood glucose >200 μg/mL (16% new)	µg/mL C2hr only DM significantly lower Median DM 31.2 (22.3-38.0), nome (22.3-38.0), nome A4.1 (24.6-42.7), d p<0.001 DM remained significant independent factor	NA 101151 29. 2023. The copyrigh	NA

Study	Country	Study Design	Number (DM/Total)	Age	Sex	Weight	Sampling	TB Treatment Phase	Dose (mg)	Regimen	TB Diagnosis	DM Diagnosis	C <sub>max</sub>	AUC	T <sub>max</sub> (Hrs)	DM Control	DM Treatment	Other PK
Ruslami 2010	Indonesia	Prospective PK	18/36	Significantly higher DM group Mean 47 (DM) versus 35 (nonDM) p0.00	Matched (42% male)	Matched (mean 47.3kg both groups)	Intensive	Intensive	1500	Rifampicin 450mg Isoniazid 300mg Pyrazinamide 1500mg Ethambutol 750mg	Pulmonary	Known (60%) Screening via WHO criteria (40%)	mg/L No difference Mean 45.5 (41.6- 49.3 95% Cl) DM V 47.0 (44.1-50.1) nonDM p0.47	0-24 mg x h/L No difference Mean 409 (369- 455) DM v 468 (422-519) nonDM p0.07	No difference Median 1 (0.5-4 range) DM v 1.5 (0.5-6) nonDM p0.61	Mean HbA1c 11.1% Median FBG 16.6mmol/L	None	No correlation between FBG and AUC/C <sub>max</sub> 10 DM cases treated with insulin to achieve glycaemic control, with PK repeated 6 weeks later – non significant change in AUC/other PK
Babalik 2013	Turkey	Prospective	14/70	Significantly higher in DM group (56.5yrs versus 39.0, p0.001)	86% DM group male, versus 61% non-DM (p0.116	DM group significantly heavier (68.7kg versus 56.7kg, p0.001)	2hr	Intensive at 14 and 30 days after starting treatment	1500	600 Rifampicin 300 Isoniazid 1500 Pyrazinamide 1000 Ethambutol Daily	Pulmonary, 89% culture confirmed	Known	C2hr only No significant difference at Date and D30 (day 14 ) mean 23.4 µg/ma. nonDM, 25.9 Date p>0.05, day 30 p>0.05, day 30 mon 27.9 nonDM vector 23.4 DM, p>0.05	NA NA 10 1101/2023 08 29 20	NA	Mean HbA1c 6.1% (only included if HbA1c <6.5%)	On treatment	
Hemanth Kumar 2016	India	Prospective PK to assess x3 weekly regimen, with DM as one covariate	23/101	Median age 34 (no breakdown of Dm group)	65.3% male (no breakdown of Dm group)	BMI significantly higher in Dm group (20.3 versus 18.4, p0.021)	2,4,6,8 hrs	Intensive	1500	Rifampicin 450/600 Isoniazid 600 Pyrazinamide 1500 Ethambutol 1200 +/- Streptomycin 750 3x weekly	Pulmonary or EP	Known of random blood glucose >200 μg/mL	μg/mL Significantly lower and DM group (28.8 – 41.6) veo thas nonDM 40.5 (34 Construction 45.0), p0.007. DM non-significant on multivariate 4.0 Intered analysis	AUC 0-8 µg/ml.hr Significantly lower in DM group Median DM 192.6 (158.4-230.4) versus nonDM 232.3 (206.0- 256.1-61.1), p<0.001 DM non- significant on multivariate analysis	2hrs for whole group – no analysis comparing DM to nonDM	Unknown	Unknown	
Kumar 2017	India	Prospective multicentre	452/1912	DM significantly older (median age DM 48yr versus 34, p<0.001)	Significantly more men in Dm group (73.5% versus 65.7, p0.002	BMI significantly higher in DM group (20.4 versus 18.2, p<0.001)	2hr	Intensive	1500	Rifampicin 450/600 Isoniazid 600 Pyrazinamide 1500 Ethambutol 1200 +/- Streptomycin 750 3x weekly	Pulmonary or EP	Known or random blood glucose >200 μg/mL (16% new)	µg/mL C2hr only DM significanty iower Median DM 31.05 (22.3-38.0), nombut 34.1 (24.6-42.7), p<0.001 DM remained significant independent factor on linear regressing	NA NA	NA	Median random blood glucose 263.5 mg/dL	Majority of diabetes group on treatment	Concentration negatively correlated with blood glucose
Alfarisi 2018	India	Prospective cohort, both PK and PK-PD	101/243	DM significantly older (median age 48 versus 26, p<0.001)	Significantly more men in DM group (77% versus 61%, p<0.001)	Weight significantiy increased in DM group (50.8kg versus 45kg, p<0.001)	0.5,2,6hrs	x1 intensive x1 continuation	1500	Rifampicin 450 Isoniazid 600 Pyrazinamide 1500 Ethambutol 1200 3x weekly Rif/Iso alone in continuation (3x weekly)	Pulmonary	Known or HbA1c >6.5%, fasting blood glucose concentration >126 mg/dl, or random blood glucose >200 mg/dl	μg/mL Significantly lower m DM group, remaining signification on adjustment Mean DM 21.59, nonDM 32.75, p0.002, adjusted	AUC0-6 µg.hr/ml Significantly lower in DM group, remaining significant on adjustment Mean DM 80.89, nonDM 128.43, p<0.001, adjusted p0.003		Median HbA1c at baseline 8.9%	44.6% on metformin	
Mtabho 2019	Tanzania	Prospective PK	19/39	DM significantly older (median age 50yrs versus 38, p0.001)	No difference in groups (79% male in DM group versus 75%)	No difference in weight (58kg DM versus 55% non, p0.258)	Intensive	Intensive	1600(>50k g), 1200 (<50kg)	Rifampicin 600/450 Isoniazid 300/225 Pyrazinamide 1600/1200 Ethambutol 1100/825 Weight cut off 50kg Daily	Clinical/radio logical/micro biological	Known or fasting glucose >7mmol/L	mg/L No significant difference Mean DM 34.5 (21.4-46.2), nonDM 38.2 (29.0-50.8) p0.09	AUC0-24 mg.h/L No significant difference Mean DM 290 (123-420), nonDM 344 (209-609), p0.08	No significant difference Median DM 1.1hrs versus 1.1hrs, p0.25	Median HbA1c 111mmol/m ol	84% on oral medications	Cmax/AUC not associated with fasting glucose or HbA1c results
Ramachan dran 2020	India	$\label{eq:properties} \begin{array}{l} {\sf Prospective} \\ {\sf PK}, \\ {\sf specifically} \\ {\sf looking at} \\ {\sf association} \\ {\sf between } {\sf C}_{2{\sf hr}} \\ {\sf and} \\ {\sf outcomes.} \end{array}$	113/404	Median age 40, no breakdown of DM group	64, no breakdown DM group	BMI Median 17.8, no breakdown DM group	2hrs	Intensive	1500	R 450/600 H 600 Z 1500 E 1200 3x weekly CP: R/H	Pulmonary	Known or HbA1c >6.5%, or RBG >200 mg/dl	μg/mL C <sub>2hr</sub> No significant difference Median 34.95 (25.03-43.42 IQR) v 37.49 (28.26-46.17), p0.08	NA	NA	Unknown	Unknown	
Kim 2023	Korea	Prospective with population PK analysis	55/613	Median age 54yrs, no breakdown DM group	67% male, no breakdown DM grouo	Weight Median 60.8kg, no breakdown DM group	Random 1- 2 samples for each patient between 0-24hrs	Intensive	20- 30mg/kg	Not specified	Microbiologi cally confirmed pulmonary	Not specified	NA	NA	NA	Unknown	Unknown	Increased apparent clearance in DM, most significantly in >70yrs group. Decreased AUC 0-24 in >70yrs DM group.

													medf					
Study	Country	Study Design	Number (DM (Total)	Age	Sex	Weight	Sampling	TB Treatment	Dose (mg)	Regimen	TB Diagnosis	DM Diagnosis		AUC	T <sub>max</sub> (Hrs)	DM Control	DM Treatment	Other PK
Heysell 2010	USA	Retrospective cohort using routinely collected data TDM carried out for patients defined as 'slow to respond'	16/39	31% 18-39, 38% 40-54, 31% >65 Total group – no break down for DM	67% male of total group (nil breakdown for DM)	Unknown	2 hr	Unknown	Unkno wn	Rifampicin Isoniazid Pyrazinamide Ethambutol Some daily, some 2x week R/H	Pulmonary or extrapulmonary Microbiologicall y confirmed	Unknown	C <sub>max</sub> define of the second s	NA	NA	Unknown	Unknown	No quantitive C <sub>max</sub> data available comparing DM and non-DM groups
Babalik 2013	Turkey	Prospective	14/70	Significantly higher in DM group (56.5yrs versus 39.0, p0.001)	86% DM group male, versus 61% non-DM (p0.116	DM group significantly heavier (68.7kg versus 56.7kg, p0.001)	2hr	Intensive at 14 and 30 days after starting treatment	300	600 Rifampicin 300 Isoniazid 1500 Pyrazinamide 1000 Ethambutol Daily	Pulmonary, 89% culture confirmed	Known	C2hr off viewer in DM group & H and D30 (day 1 finge 3.2 µg/mL nonDME10 DM, p<0.05, day 30 file DM, p<0.05)	NA	NA	Mean HbA1c 6.1% (only included if HbA1c <6.5%)	On treatment	Concentration inversely correlated with weight
Requena-Mendez 2014	Peru	Prospective field PK assessing daily and x2 weekly dosing in DM, HIV and nonDM/HIV groups	25/107 (30 HIV, 52 nonDM/non HIV)	DM significantly older (median 50yrs, versus 29yrs p<0.001)	64% DM male, versus 50% TB group (p0.2)	BMI significantly increased in DM group (median 27 versus 22.9, p<0.001)	2, 6 hrs	1 sampling event from each participant, 57.9% overall in intensive phase, rest in continuation	5mg/k g intensi ve phase, 15mg/ kg contin uation phase, up to 800mg	Rest of regimen not specified Daily in intensive phase, x2/week in continuation	72.9% microbiologicall y confirmed	Known	No significant difference between By concerned by groups (daily concerned b	AUC 0.6 - mg.hr/L No significant difference between DM/non-DM in daily or x2 weekly groups (daily group: median 10.39 DM, 11.05 non-DM, p0.6, x2 weekly: median 54.26 DM, 62.45 nonDM, p0.2	86.4% total highest concentration at 2hrs in daily group, 90.7 in x2/weekly group. No comment on any differences in DM group	Median random blood glucose 119.5mg/dL	Unknown	Highly variable concentrations in all groups, with >30% not reaching target concentrations.
Hemanth Kumar 2016	India	Prospective PK to assess x3 weekly regimen, with DM as one covariate	23/101	Median age 34 (no breakdown of Dm group)	65.3% male (no breakdown of Dm group)	BMI significantly higher in Dm group (20.3 versus 18.4, p0.021)	2,4,6,8 hrs	Intensive	600	Rifampicin 450/600 Isoniazid 600 Pyrazinamide 1500 Ethambutol 1200 +/- Streptomycin 750 3x weekly	Pulmonary or EP	Known of random blood glucose >200 µg/mL	µg/mL No signification MediancDA (8.5 – 12.4) varses fonDM 11.5 (8.5 – 13.5) v0.17 00.17 00.000000	AUC 0-8 μg/ml.hr No significant difference Median DM 37.8 (22.9-53.9) versus nonDM 42.9 (34.2- 61.1), p0.08	2hrs for whole group – no analysis comparing DM to nonDM	Unknown	Unknown	DM not significant as a factor on multivariate analysis (Cmax and AUC)
Kumar 2017	India	Prospective multicentre	452/1912	DM significantly older (median age DM 48yr versus 34, p<0.001)	Significantly more men in Dm group (73.5% versus 65.7, p0.002	BMI significantly higher in DM group (20.4 versus 18.2, p<0.001)	2hr	Intensive	600	Rifampicin 450/600 Isoniazid 600 Pyrazinamide 1500 Ethambutol 1200 +/- Streptomycin 750 3x weekly	Pulmonary or EP	Known or random blood glucose >200 µg/mL (16% new)	µg/mL. 6 0 C2hr only 5 1 DM signift@ Yiy lower Median D & 6 (3.9-10), nonDM 7.5 (± 6-11.3), p<0.001 0 DM rematigent significant independ ∰ @actor on linear reget sign	NA	NA	Median random blood glucose 263.5 mg/dL	Majority of diabetes group on treatment	Concentration negatively correlated with blood glucose
Alfarisi 2018	India	Prospective cohort, both PK and PK-PD	101/243	DM significantly older (median age 48 versus 26, p<0.001)	Significantly more men in DM group (77% versus 61%, p<0.001)	Weight significantly increased in DM group (50.8kg versus 45kg, p<0.001)	0.5,2,6hrs	x1 intensive x1 continuation	600	Rifampicin 450 Isoniazid 600 Pyrazinamide 1500 Ethambutol 1200 3x weekly Rif/Iso alone in continuation (3x weekly)	Pulmonary	Known or HbA1c >6.5%, fasting blood glucose concentra tion >126 mg/dl, or random blood glucose >200 mg/dl	µg/mL ⋽ Significant after adjuggenent Intensive and m DM 5.97, nonDM3.91, p0.03, adjusted p0.08 Continuation: mean DM 7.42, nonDM 7.63, p0.86	AUC0-6 µg.hr/ml Significantly lower in DM group, not significant after adjustment Intensive: mean DM 20.0, nonDM 26.84, p0.03, adjusted p0.06 Continuation: mean DM 23.79, nonDM 26.79 p0.45		Median HbA1c at baseline 8.9%	44.6% on metformin	
Mtabho 2019	Tanzania	Prospective PK	19/39	DM significantly older (median age 50yrs versus 38, p0.001)	No difference in groups (79% male in DM group versus 75%)	No difference in weight (58kg DM versus 55% non, p0.258)	Intensive	Intensive	300 (>50kg ), 225 (<50kg )	Rifampicin 600/450 Isoniazid 300/225 Pyrazinamide 1600/1200 Ethambutol 1100/825 Weight cut off 50kg Daily	Clinical/radiologi cal/microbiologi cal	Known or fasting glucose >7mmol/L	mg/L Significantly lower in DM group Mean DM 1.6 (0.4-5.8), nonDM 2.8 (1.0-4.6) p0.0.01	AUC0-24 mg.h/L Significantly lower in DM group Mean DM 5.4 (0.7- 26.9), nonDM 10.6(3.7-22.7), p0.01	No significant difference Median DM 1.0hrs versus 1.1hrs, p0.85	Median HbA1c 111mmol/m ol	84% on oral medications	Cmax/AUC not associated with fasting glucose or HbA1c results DM significantly associated with Cmax and AUC on multivariate regression
Galvao 2020	Brazil	Prospective PK	26/62	No difference (median 39yrs versus 44)	100%	Weight significantly higher in DM group (Median 64kg versus 54kg)	2hrs	Intensive and Continuation	300	Rifampicin 600 Isoniazid 300 Pyrazinamide 1600 Ethambutol 1100 Daily R/H only in continuation	Pulmonary, clinical, radio, micro	Fasting glucose >126 mg/dl or HbA1c >6.5%	µg/mL C2hr only No significant difference Intensive: Median DM 4.82 (3.47-5.5 IQR) versus nonDM 5.0 (4.1- 5.5), p0.43. Continuation: Median DM 3.76 (4.1-5.5) versus nonDM 4.15 (3.82-5.18),			Median HbA1c 9.6%	15% on treatment	No association between concentrations and HbA1c/FBG

													p0.38				
amachandran 2020	India	Prospective	113/404	Median age	64, no	BMI	2hrs	Intensive and	600	R 450/600	Pulmonary	Known or	µg/mL S	NA	NA	Unknown	Unknown
		PK,		40, no	breakdown DM	Median 17.8,		Continuation		H 600		HbA1c					
		specifically		breakdown	group	no				Z 1500		>6.5%, or	No sign				
		looking at		of DM group		breakdown				E 1200		RBG >200	differe				
		association				DM group				3x weekly		mg/dl	Mth 1: 🎢 🛱 ian				
		between C <sub>2hr</sub>								CP: R/H			5.05 (2 <b>2</b> 94 <u>5</u> 7.34				
		and											IQR) v 🚟 🦉 (2.68-				
		out com es.											8.28), 📸 🍇 Mth 5: 5. <b>92</b> 🙆 17-7.89) v				
													6.63 (3.491009), p0.10				

made available under a CC-BY-NC-ND 4.0 International license.	<b>view)</b> is the author/funder, who has granted medRxiv a license to display the preprint in perpe	1101/2023.08.29.23294656; this version posted August 29, 2023. The copyright holder for this	
	it in perpetuity.	ler for this preprint	

Chudu	Country	Study Desire	1 Number		Car	Weishe	Compliant	TD Treatment	Dece (mg)	Desimon	TP Discresio		medRxiv preprint ( (which was no		T (life)			Other DV
Study	Country	Study Design	(DM/Total)	Age	JEX	weignt	Samhung	Phase	Dose (mg)	regimen	ID DIAGUOSIS			AUC	י <sub>max</sub> (רוי)		Treatment	
Ruslami 2010	Indonesia	Prospective	17/34	Significantly higher DM group Mean 47 (DM) versus 35 (nonDM) p0.00	Matched (42% male)	Matched (within 5kg) (mean 47.3kg both groups)	Intensive	Intensive	750	Rifampicin 450mg Isoniazid 300mg Pyrazinamide 1500mg Ethambutol 750mg	Pulmonary	Known (60%) Screening via WHO criteria (40%)	mg/L No difference 57 Mean 2.2 (1.9 57 95% Cl) DM 50 1.95 (1.6-2.45 0.0 nonDM p0.38	0-24 mg x h/L No difference Mean 13.8 (12.0-15.9) DM v 13.5 (12.0- 15.1) nonDM p0.77	No difference Median 3 (1-4 range) DM v 3 (1- 6) nonDM p0.93	Mean HbA1c 11.1% Median FBG 16.6mmol/L	None	No correlation between FBG and AUC/C <sub>max</sub> 10 DM cases treated with insulin to achieve glycaemic control, with PK repeated 6 weeks later – non significant change in AUC/other PK
Babalik 2013	Turkey	Prospective	14/70	Significantly higher in DM group (56.5yrs versus 39.0, p0.001)	86% DM group male, versus 61% non-DM (p0.116	DM group significantly heavier (68.7kg versus 56.7kg, p0.001)	2hr	Intensive at 14 and 30 days after starting treatment	1000	600 Rifampicin 300 Isoniazid 1500 Pyrazinamide 1000 Ethambutol Daily	Pulmonary, 89% culture confirmed	Known	C2hr only men of the component of the c	NA	NA	Mean HbA1c 6.1% (only included if HbA1c <6.5%)	On treatment	
Mtabho 2019	Tanzania	Prospective PK	19/39	DM significantly older (median age 50yrs versus 38, p0.001)	No difference in groups (79% male in DM group versus 75%)	No difference in weight (58kg DM versus 55% non, p0.258)	Intensive	Intensive	1100 (>50kg), 825 (<50kg)	Rifampicin 600/450 Isoniazid 300/225 Pyrazinamide 1600/1200 Ethambutol 1100/825 Weight cut off 50kg Daily	Clinical/radio logical/micro biological	Known or fasting glucose >7mmol/L	mg/L Cert No signification this very difference of the symposic (1.3-6.3), room post 3.3 (2.2-5) of an post p0.67 4 content of the symposic the symposic p0.67 4 content of the symposic the symposic th	AUC0-24 mg.h/L No significant difference Mean DM 19.6 (7.5-40.4), nonDM 20.2 (13.4-32.0), p0.78	No significant difference Median DM 2.0hrs versus 2.0hrs, p0.31	Median HbA1c 111mmol/m ol	84% on oral medicatio ns	Cmax/AUC not associated with fasting glucose or HbA1c results

# Other

medRxiv preprir **(which was** 

													3	<u>p</u>				
Study	Agent	Country	Study Design	Number (DM/Total)	Age	Sex	Weight	Sampling	TB Treatment Phase	Dose (mg)	Regimen	TB Diagnosis	DM 🔒	C <sub>max</sub>	AUC	DM Control	DM Treatment	Other PK
Zhu 2018	Cycloserine	China	Retrospective – all cases receiving TDM last 4 years, DM a covariant	19/200	Mean 35.8, no b/down DM group	63% male, no breakdown Dm group	Mean BMI 21.3, no b/down DM group	2hr	Unknown	500 <50kg 750 >50kg	Unknown	Unknown	Known rtified by pee	NA	NA	Unknown	Unknown	Normal range 20-35 µg/ml No significant difference in % DM with low concentrations DM 68% low v nonDM 60% low (p0.427)
Zhu 2018	Linezolid	China	Retrospective – all cases receiving TDM last 4 years, DM a covariant	6/65	Mean 34.7, no b/down DM group	52% male, no b/down DM group	Mean BMI 21.2, no b/down DM group	2hr	Unknown	600	Unknown	Unknown	r review) is the triss made avai	NA	NA	Unknown	Unknown	Normal range 12-26 µg/ml No significant difference in % DM with low concentrations DM 17% low v nonDM 21% low (p1.00)
Dekkers 2019	Moxifloxacin	The Netherlands	Retrospective – all DM cases receiving moxi TDM over 12 yrs with matched controls	16/32	Matched Median 52 (DM) v 49 (nonDM)	Matched 69% male (DM) v 63% male (nonDM)	BMI - No signif difference 21.9 (DM) v 20.7 (nonDM)	Varied, median 6-7 samples	Intensive	6.5- 6.6mg/kg	Varied	50% pTB (DM), 75% pTB (nonDM) 31% MDR (DM), 38% MDR (nonDM)	e author/funder, who h æle under a CC-BY-h Kn	Mg/L Significantly lower in DM Median DM 1.7 (IQR 1.3- 2.6) v nonDM 2.4 (2.0-3.0), p<0.05	0-24 mg.hr/L Significantly Iower in DM Median DM 17.4 (IQR 12.5-21.8) v nonDM 23.2 (16.8-32.1), p<0.05	Median HbA1c 8.3% (only in 9 patients)	14/16 receiving insulin	Clearance increased in DM group No difference in Tlag/ka

his version posted August 29, 2023. The copyright holder for this preprint no has granted medRxiv a license to display the preprint in perpetuity. 3Y-NC-ND 4.0 International license .